Email this article to a friend
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
-
* Corresponding author: Roberto Ravasio Roberto.Ravasio@wolterskluwer.com
- † Equal contributors
Italian Journal of Pediatrics 2009, 35:4 doi:10.1186/1824-7288-35-4